Biomarker Resource Center
Waldenström Macroglobulinemia Biomarkers
Reviewed by XpertPatient Medical Advisory · Updated September 2026 · Primary Source: iwmf.com
Start Here
What is a biomarker?
A biomarker in Waldenström macroglobulinemia (WM) is a signal found in your bone marrow cells or blood. Two biomarkers matter most: MYD88 mutation status and CXCR4 mutation status. Together they tell your doctor how confident the diagnosis is and which treatment approaches will work best for your disease.
Think of it like a clue. Your doctor collects clues from your biomarker test results. Those clues help build a picture of your disease. That picture helps you have a more informed conversation with your care team about next steps. Everyone’s WM is different — even people with the same diagnosis can have very different results.
Why Do Biomarkers Matter in WM?
WM was long grouped in with other lymphomas until researchers found that nearly all patients share the same MYD88 mutation — giving the disease a clear molecular signature and a target for newer therapies. Knowing your results can change which treatment your doctor reaches for first.
The most important WM biomarkers are MYD88 L265P mutation status and CXCR4 mutation status. Together they shape your entire treatment approach.
A good question to ask your doctor: Ask your doctor for both your MYD88 result and your CXCR4 result before treatment begins.
Patient Poll
Have you had biomarker testing for your Waldenström macroglobulinemia?
The Tests Your Doctor Orders
Is this really Waldenström macroglobulinemia?
MYD88 L265P is present in roughly 90 to 95% of WM patients and is now considered a near-defining feature of the disease. It is usually the first genetic test ordered after a bone marrow biopsy, and several targeted drugs work specifically because of this mutation. Ask your doctor whether MYD88 testing has been done and what your result is.
Will standard BTK-inhibitor treatment work as well?
Found in roughly 30 to 40% of WM patients, CXCR4 mutations are linked to a slower, more resistant response to BTK inhibitors like ibrutinib. Patients with this mutation often need a longer treatment course or a different combination approach from the start. Ask your doctor what your CXCR4 result is.
Is the disease active, and is treatment working?
IgM is the antibody WM cells overproduce, and a simple blood test tracks it over time. A falling IgM level is one of the clearest signs treatment is working; a rising one — especially with nosebleeds, headaches, or vision changes — can signal hyperviscosity that needs prompt attention. Ask your doctor how your IgM has trended.
What’s the overall prognostic outlook?
Along with age, hemoglobin, and platelet count, beta-2 microglobulin is one of the factors used in the International Prognostic Scoring System for WM (IPSSWM) to sort patients into risk groups — helping guide how closely you are monitored. Ask your doctor what your risk category is.
Sources: IWMF · National Cancer Institute · American Society of Hematology
Watch & Learn
Important: This page is for education only. It is not medical advice. Every patient’s situation is different. Please talk to your doctor about what your results mean for you specifically.
Common Questions
WM Biomarkers — Your Questions Answered
What is the difference between MYD88 and CXCR4 mutations?
MYD88 L265P is present in roughly 90 to 95% of WM patients and is used to confirm the diagnosis. CXCR4 is a second mutation found in about a third of patients and is linked to a slower, more resistant response to BTK-inhibitor treatment, so it shapes which therapy your doctor recommends first.
Do I need biomarker testing before starting treatment?
Yes. Most hematologists order MYD88 and CXCR4 testing on a bone marrow sample before choosing a treatment, since the results affect whether a BTK inhibitor is likely to work well on its own or whether a combination approach makes more sense.
What if I don’t have the MYD88 mutation?
A small percentage of WM patients test negative for MYD88. Your care team will look more closely at other markers and may reconsider the diagnosis, since MYD88-negative lymphoplasmacytic lymphoma can behave differently and may need a different approach.
Should I see a specialist?
Yes. Waldenström macroglobulinemia is rare, and outcomes are generally best with a hematologist-oncologist experienced in WM specifically. Seek care at a center with WM expertise, or ask for a second opinion from one.
Quick Links
From the Waldenström Macroglobulinemia Center on XpertPatient
Have questions about your diagnosis?
XpertPatient is a free, survivor-led education resource for newly diagnosed cancer patients.
Visit the WM Center → Full Biomarkers Guide
